2 H.O B. nB(B :w è% (üB BV .;BgB B B¤B...
Transcript of 2 H.O B. nB(B :w è% (üB BV .;BgB B B¤B...
.............................................................................................................................................................3
...................................................................................................4
......................................................................................................................................................5
...............................................................................................................................................6
......................................................................................................................................................7
......................................................................................................................................................8
.................................................................................................................... 8........................................................................................................................ 9
ANALYTIC FRAMEWORK ....................................................................................................... 9......................................................................................................................................... 10
............................................................................................ 11.......................................................................................................................... 12
...................................................................................................................... 12......................................................................................................................................... 13
....................................................................................................................................................14
............................................................................................................................. 14
............................................................................................................................. 15 ............................................................................................................................. 15 (PSA) ..................................................................................................... 16
.....................................................................................................................................23
....................................................................................................................................................24
..................................................................................................................................... 24...................................................................................................................... 25...................................................................................................................... 26
.............................................................................................................. 28.................................................................................... 29
......................................................................... 30............................................................................. 31
............................................................................................................................. 32
.............................................................................................................................................34
...........................................................................................................................................................35
3
2-
PSA 1-/2-
PSA
4
Analytic Framework
MEDLINE
DARE HTA
PSA
PSA
PSA
PSA
PSA
PSA
5
6
7
Analytic Framework AF
2
2.
NICE National Institute for Health and Clinical Excellence
CDC(Centers for Disease Control and Prevention)
Community Guide
GRADE
USPSTF(US Preventive Services Task Force) CTFPHC(Canadian Task Force on Preventive Health Care)
2+
2-
8
9
10
11
12
13
1985 1 1 2006
MEDLINE374 DARE43 MEDLINE 2006 10 1
DARE 2006 9 16 ERSPC (European Randomized Study of Screening for Prostate
Cancer) PLCO Prostate, Lung, Colorectal and Ovarian Cancer Trial)
2006 10 1 MEDLINE DARE 145
573
2006 9 19 30
21
2 1 5
52 7
65 7
72 117 14
2
1 44 1
54 25
23 2 67 3
16 19
2
64 1
1
9 2
USPSTF 5
4 2
69 3
33
2 18
81 13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, Graham E, Echols RM,
Whalen E, Kowalsky SF. Single-dose oral ciprofloxacin versus placebo for prophylaxis during
transrectal prostate biopsy. Urology. 1998;52(4):552-558.
Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD.
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal
examination and prostate specific antigen. J Urol. 2002;167(2 Pt 2):966-975.
Rodrguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle
biopsy: a prospective study and review of the literature. J Urol. 1998;160(6 Pt 1):2115-2120.
Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C,
Marberger M.. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle
biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001;166(3):
856-860.
Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk
factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a
population-based screening program. Urology. 2002;60(5):826-830.
Crawford ED, Haynes AL Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis
following transrectal prostatic biopsy. J Urol. 1982;127(3):449-451.
Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a
randomized controlled study. BJU Int. 2000;85(6):682-685.
Norberg M, Holmberg L, Hggman M, Magnusson A. Determinants of complications after multiple
transrectal core biopsies of the prostate. Eur Radiol. 1996;6(4):457-461.
, , , , .
1 2002;93(5):648-651.
, , , , , , , ,
, , . 1 .
. 2002;76(10):893-897.
Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC,
Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate
cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354-360.
Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. The use of
treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer. 2002;95(11):
2397-2407.
Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time
trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA.
1993;269:2633-2636.
Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norln BJ, Holmberg L. Quality of
life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790-796.
40
41
42
43
44